X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   MYLAN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
MYLAN
Dec-14
VENUS REMEDIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1264,298-   
Low Rs613,029-   
Sales per share (Unadj.) Rs301.81,471.5-  
Earnings per share (Unadj.) Rs-24.9177.3-  
Cash flow per share (Unadj.) Rs2.5285.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.3731.5-  
Shares outstanding (eoy) m12.34378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x0.32.5 12.4%   
Avg P/E ratio x-3.820.7 -18.2%  
P/CF ratio (eoy) x36.712.8 286.2%  
Price / Book Value ratio x0.35.0 6.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1541,386,233 0.1%   
No. of employees `0000.925.0 3.7%   
Total wages/salary Rs m3930-   
Avg. sales/employee Rs Th4,026.122,270.7 18.1%   
Avg. wages/employee Rs Th425.00-   
Avg. net profit/employee Rs Th-331.82,682.9 -12.4%   
INCOME DATA
Net Sales Rs m3,724556,766 0.7%  
Other income Rs m23-3,245 -0.7%   
Total revenues Rs m3,747553,521 0.7%   
Gross profit Rs m395138,470 0.3%  
Depreciation Rs m33840,892 0.8%   
Interest Rs m35424,016 1.5%   
Profit before tax Rs m-27570,317 -0.4%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322,957 1.1%   
Profit after tax Rs m-30767,072 -0.5%  
Gross profit margin %10.624.9 42.6%  
Effective tax rate %-11.54.2 -273.0%   
Net profit margin %-8.212.0 -68.4%  
BALANCE SHEET DATA
Current assets Rs m2,638489,471 0.5%   
Current liabilities Rs m2,305382,669 0.6%   
Net working cap to sales %8.919.2 46.6%  
Current ratio x1.11.3 89.5%  
Inventory Days Days13578 173.5%  
Debtors Days Days46107 43.2%  
Net fixed assets Rs m4,871128,806 3.8%   
Share capital Rs m12319,689 0.6%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,619276,768 1.3%   
Long term debt Rs m1,374413,464 0.3%   
Total assets Rs m7,5091,114,795 0.7%  
Interest coverage x0.23.9 5.7%   
Debt to equity ratio x0.41.5 25.4%  
Sales to assets ratio x0.50.5 99.3%   
Return on assets %0.68.2 7.7%  
Return on equity %-8.524.2 -35.0%  
Return on capital %1.613.6 11.6%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m51473,187 0.7%  
From Investments Rs m-123-57,718 0.2%  
From Financial Activity Rs m-387-19,285 2.0%  
Net Cashflow Rs m4-3,815 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.12 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: SHASUN PHARMA  NATCO PHARMA  GSK PHARMA  PFIZER  TTK HEALTHCARE  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 15, 2018 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS